Cardiovascular Drugs and Therapy最新文献

{"title":"Flavonoids for Myocardial Ischemia-Reperfusion Injury?","authors":"Yochai Birnbaum, Gemma Vilahur","doi":"10.1007/s10557-025-07688-z","DOIUrl":"10.1007/s10557-025-07688-z","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"705-706"},"PeriodicalIF":3.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Effectiveness of Antidysrhythmic Drugs for Pharmacologic Cardioversion of Recent-Onset Atrial Fibrillation: a Systematic Review and Bayesian Network Meta-analysis.","authors":"Ian S deSouza, Pragati Shrestha, Robert Allen, Jessica Koos, Henry Thode","doi":"10.1007/s10557-024-07552-6","DOIUrl":"10.1007/s10557-024-07552-6","url":null,"abstract":"<p><strong>Purpose: </strong>The available evidence to determine which antidysrhythmic drug is superior for pharmacologic cardioversion of recent-onset (onset within 48 h) atrial fibrillation (AF) is uncertain. We aimed to identify the safest and most effective agent for pharmacologic cardioversion of recent-onset AF in the emergency department.</p><p><strong>Methods: </strong>We searched MEDLINE, Embase, and Web of Science from inception to February 21, 2023 (PROSPERO: CRD42018083781). Eligible studies were randomized controlled trials that enrolled adult participants with AF ≤ 48 h, compared a guideline-recommended antidysrhythmic drug with another antidysrhythmic drug or a different formulation of the same drug or placebo and reported specific adverse events. The primary outcome was immediate, serious adverse event - cardiac arrest, sustained ventricular tachydysrhythmia, atrial flutter 1:1 atrioventricular conduction, hypotension, and bradycardia. Additional analyses included the outcomes of conversion to sinus rhythm within 4 h and 24 h. We extracted data according to PRISMA-NMA and appraised trials using Cochrane RoB 2. We performed Bayesian network meta-analysis (NMA) using a Markov Chain Monte Carlo method with random-effect model and vague prior distribution to calculate odds ratios with 95% credible intervals. We assessed confidence using CINeMA. We used surface under the cumulative ranking curve (SUCRA) to rank agent(s).</p><p><strong>Results: </strong>The systematic review initially identified 5545 studies. Twenty-five studies met eligibility criteria, and 22 studies (n = 3082) provided data for NMA, which demonstrated that vernakalant (SUCRA = 70.9%) is most likely to be safest. Additional effectiveness NMA demonstrated that flecainide (SUCRA = 89.0%) is most likely to be superior for conversion within 4 h (27 studies; n = 2681), and ranolazine-amiodarone IV (SUCRA 93.7%) is most likely to be superior for conversion within 24 h (24 studies; n = 3213). Confidence in the NMA estimates is variable and limited mostly by within-study bias and imprecision.</p><p><strong>Conclusions: </strong>Among guideline-recommended antidysrhythmic drugs, the combination of digoxin IV and amiodarone IV is definitely among the least safe for cardioversion of recent onset AF; flecainide, vernakalant, ibutilide, propafenone, and amiodarone IV are definitely among the most effective for cardioversion within 4 h; flecainide is definitely among the most effective for cardioversion within 24 h. Further, randomized controlled trials with predetermined and strictly defined, hemodynamic adverse event outcomes are recommended.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"903-923"},"PeriodicalIF":3.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139697024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyperkalaemia in Cardiological Patients: New Solutions for an Old Problem.","authors":"Maurizio Giuseppe Abrignani, Edoardo Gronda, Marco Marini, Mauro Gori, Massimo Iacoviello, Pier Luigi Temporelli, Manuela Benvenuto, Giulio Binaghi, Arturo Cesaro, Alessandro Maloberti, Maria Denitza Tinti, Carmine Riccio, Furio Colivicchi, Massimo Grimaldi, Domenico Gabrielli, Fabrizio Oliva","doi":"10.1007/s10557-024-07551-7","DOIUrl":"10.1007/s10557-024-07551-7","url":null,"abstract":"<p><p>Hyperkalaemia is one of the most common electrolyte disorders in patients with cardiovascular disease (CVD). The true burden of hyperkalaemia in the real-world setting can be difficult to assess, but in population-based cohort studies up to 4 in 10 patients developed hyperkalaemia. In addition to drugs interfering with potassium metabolism and food intake, several conditions can cause or worsen hyperkalaemia, such as advanced age, diabetes, and chronic kidney disease. Mortality, cardiovascular morbidity, and hospitalisation are higher in patients with hyperkalaemia. Hyperkalaemia represents a major contraindication or a withholding cause for disease-modifying therapies like renin-angiotensin-aldosterone inhibitors (RAASi), mainly mineralocorticoid receptor antagonists. Hyperkalaemia can be also classified as acute and chronic, according to the onset. Acute hyperkalaemia is often a life-threatening emergency requiring immediate treatment to avoid lethal arrhythmias. Therapy goal is cell membrane stabilisation by calcium administration, cellular intake, shift of extracellular potassium to the intracellular space (insulin, beta-adrenergic agents, sodium bicarbonate), and increased elimination with diuretics or dialysis. Chronic hyperkalaemia was often managed with dietary counselling to prevent potassium-rich food intake and tapering of potassium-increasing drugs, mostly RAASi. Sodium polystyrene sulphonate, a potassium binder, was the only therapeutic option. Recently, new drugs such as patiromer and sodium zirconium cyclosilicate give new opportunities for the treatment of hyperkalaemia, as they proved to be safe, well tolerated, and effective. Aim of this review is to describe the burden of hyperkalaemia in cardiovascular patients, its direct and indirect effects, and the therapeutic options now available in the acute and chronic setting.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"857-874"},"PeriodicalIF":3.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139575193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Angiography-based Fractional Flow Reserve for the Prediction of Clinical Outcomes After Drug-coated Balloon or Plain Old Balloon Angioplasty.","authors":"Wei Wang, Xinyi Yang, Yumeng Hu, Xiaochang Leng, Jianping Xiang, Xianhe Lin","doi":"10.1007/s10557-024-07575-z","DOIUrl":"10.1007/s10557-024-07575-z","url":null,"abstract":"<p><strong>Background: </strong>AccuFFRangio is a novel method for fast computation of fractional flow reserve (FFR) based on coronary angiography and computational fluid dynamics. The association between the AccuFFRangio and clinical outcomes after drug-coated balloon (DCB) or plain old balloon angioplasty (POBA) remains to be investigated.</p><p><strong>Methods: </strong>This study included consecutive patients who underwent balloon angioplasty from December 2016 to October 2020. AccuFFRangio was calculated retrospectively based on the post-procedural angiography obtained immediately after angioplasty. The primary endpoint was major adverse cardiac events (MACE), defined as a composite of all-cause death, vessel-related myocardial infarction, and repeat target vessel revascularization.</p><p><strong>Results: </strong>A total of 169 patients were retrospectively analyzed in this study. Post-procedural AccuFFRangio (hazard ratio [HR] per 0.1 increase 0.33, 95% confidence interval [CI] 0.22-0.48, p < 0.001) was an independent predictor for MACE at 2-year follow-up. Post-procedural AccuFFRangio ≤ 0.87 was determined as the optimal cutoff value to predict MACE with an area under the curve (AUC) of 0.872 (95% CI 0.813-0.919, p < 0.001).</p><p><strong>Conclusions: </strong>AccuFFRangio measured immediately after balloon angioplasty is a promising predictor of unfavorable clinical outcomes.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"791-800"},"PeriodicalIF":3.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141157880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Function of Circular RNAs in Myocardial Ischemia-Reperfusion Injury: Underlying Mechanisms and Therapeutic Advancement.","authors":"Kai-Yuan Chen, Zhou Liu, Jun-Hou Lu, Si-Yuan Yang, Xuan-Yi Hu, Gui-You Liang","doi":"10.1007/s10557-024-07557-1","DOIUrl":"10.1007/s10557-024-07557-1","url":null,"abstract":"<p><p>Myocardial ischemia reperfusion injury (MIRI) represents a prevalent and severe cardiovascular condition that arises primarily after myocardial infarction recanalization, cardiopulmonary bypass surgery, and both stable and unstable angina pectoris. MIRI can induce malignant arrhythmias and heart failure, thereby increasing the morbidity and mortality rates associated with cardiovascular diseases. Hence, it is important to assess the potential pathological mechanisms of MIRI and develop effective treatments. The role of circular RNAs (circRNAs) in MIRI has increasingly become a topic of interest in recent years. Moreover, significant evidence suggests that circRNAs play a critical role in MIRI pathogenesis, thereby representing a promising therapeutic target. This review aimed to provide a comprehensive overview of the current understanding of the role of circRNAs in MIRI and discuss the mechanisms through which circRNAs contribute to MIRI development and progression, including their effects on apoptosis, inflammation, oxidative stress, and autophagy. Furthermore, the potential therapeutic applications of circRNAs in MIRI treatment, including the use of circRNA-based therapies and modulation of circRNA expression levels, have been explored. Overall, this paper highlights the importance of circRNAs in MIRI and underscores their potential as novel therapeutic targets.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"875-886"},"PeriodicalIF":3.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139575195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quercetin and Cardiac Fibrosis-Promise or Polyphenolic Placebo?","authors":"Yochai Birnbaum, Kim Connely","doi":"10.1007/s10557-025-07705-1","DOIUrl":"10.1007/s10557-025-07705-1","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"707-708"},"PeriodicalIF":3.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dying for Clarity: Common Pitfalls in Cardiac Cell Death Research.","authors":"Alexander J Wehrens, Jason Karch","doi":"10.1007/s10557-025-07756-4","DOIUrl":"https://doi.org/10.1007/s10557-025-07756-4","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144741294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Bisoprolol Versus Other Beta-Blockers on Glycemic Control and Metabolic Parameters in Type 2 Diabetes: A Retrospective Cohort Study.","authors":"Sivan Gazit, Yogev Yonatan, Moshe Baruch Hoshen, Felix Mahfoud, Tal Tova Patalon","doi":"10.1007/s10557-025-07753-7","DOIUrl":"https://doi.org/10.1007/s10557-025-07753-7","url":null,"abstract":"<p><strong>Purpose: </strong>β-blockers (BB) are a heterogeneous class of medications guideline-recommended for heart failure (HF) and diabetes mellitus (DM). However, physicians may be reluctant to prescribe BBs due to concerns regarding negative metabolic effects. The primary objective was to assess the short-term change in glucose control in PwT2DM (patients with T2DM) who initiated bisoprolol versus the reference cohorts. Secondary objectives were to assess change in lipid control, and proportion of patients with hypoglycemic events during follow-up in PwT2DM who initiated bisoprolol.</p><p><strong>Methods: </strong>We performed a retrospective cohort study of T2DM patients on bisoprolol compared to no treatment, carvedilol, other selective BBs, or nonselective BBs. Anonymized data was collected from the Maccabi Health Services (MHS) database between 2003 and 2023.</p><p><strong>Results: </strong>A total of 12,981 records were analyzed. The reduction in HbA1C (difference of -0.05 [-0.09, -0.01]), fasting plasma glucose (FPG) (difference of -1.72 [-3.35, -0.1]), and cholesterol measures (total, HDL, LDL differences of -9.12 [-10.94, -7.31], -0.94 [-1.24, -0.65], and -7.89 [-9.53, -6.26], respectively) was significantly greater in the bisoprolol cohort compared to reference cohort 1 (no treatment). In cohort 2, the reduction in HbA1C was significantly greater with carvedilol users compared to bisoprolol users (difference of 0.34 [0.04, 0.63]). The reduction in total cholesterol and LDL was significantly greater in the bisoprolol cohort compared to reference cohort 4 (nonselective BB users, differences of -5.86 [-9.46, -2.25] and -7.08 [-10.25, -3.92], respectively).</p><p><strong>Conclusion: </strong>Bisoprolol had a neutral effect on the glycemic profile with a statistically beneficial impact on the lipid profile, comparable to carvedilol.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: The Beta-Blocker Dilemma: Revisiting Their Role in Cardiovascular Disease.","authors":"Matthew Fordham, Radmila Lyubarova, Mandeep Sidhu","doi":"10.1007/s10557-025-07755-5","DOIUrl":"https://doi.org/10.1007/s10557-025-07755-5","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Low-Dose Dexmedetomidine as an Anesthetic Adjuvant on Intraoperative Hemodynamics and Prognosis in Patients Undergoing Cardiac Surgery.","authors":"Zhi-Wei Fan, Shi-Liang Li, Yu-Xian Tang, Wei-Min Qiang, Yu-Ting Wu, Jun-Yuan Ge, Lin-Wei Chen, Kun-Sheng Li","doi":"10.1007/s10557-025-07713-1","DOIUrl":"https://doi.org/10.1007/s10557-025-07713-1","url":null,"abstract":"<p><strong>Purpose: </strong>Dexmedetomidine, as an anesthetic adjuvant, has a guideline-recommended dose of 0.2-0.7 µg/kg/h. We sought to compare the intraoperative hemodynamic and prognostic performance of cardiac surgical patients receiving the guideline-recommended dose of dexmedetomidine to those receiving a dose lower than the guideline.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted on 871 patients who were maintained under anesthesia with dexmedetomidine during cardiac surgery, of whom 414 patients received the guideline-recommended dose as a control group and 457 below the guideline-recommended dose as a low-dose group. A cohort of patients in the low-dose and control group (155 vs 155) was created by propensity score matching. The primary outcome was a composite of adverse outcomes, including bradycardia, atrial fibrillation, and hypotension. Secondary outcomes assessed included delirium, analgesic medication use, cardiac intensive care unit (CICU) length of stay, and duration of mechanical ventilation.</p><p><strong>Results: </strong>After propensity matching, the maximum heart rate difference, maximum systolic blood pressure difference, maximum diastolic blood pressure value, and maximum mean arterial pressure difference before and after cardiopulmonary bypass and after cessation of pumping were significantly different in the low-dose group compared with the control group (P < 0.01). Compared with the control group, the low-dose group had a higher incidence of postoperative atrial fibrillation (34.8% vs. 23.9%, P = 0.034), and the length of stay in the cardiac intensive care unit (median 4 days, quartiles 3-5 days vs. median 3 days, quartiles 3-4 days, P < 0.001) was significantly longer.</p><p><strong>Conclusion: </strong>Compared with lower dose, receiving dexmedetomidine pumped at the guideline-recommended dose in anesthetic assistance for cardiac surgery resulted in smoother intraoperative hemodynamic performance and an improvement in the incidence of postoperative atrial fibrillation, shorter stay in the cardiac intensive care unit, and better prognostic performance.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144717619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}